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Abstract
Background: We previously reported the results of a multicentric prospective randomized trial of chemo-refractory
metastatic breast cancer patients testing the efficacy of two doses of TGFβ blockade during radiotherapy. Despite a
lack of objective responses to the combination, patients who received a higher dose of TGFβ blocking antibody
fresolimumab had a better overall survival when compared to those assigned to lower dose (hazard ratio of 2.73,
p = 0.039). They also demonstrated an improved peripheral blood mononuclear cell (PBMC) counts and increase in
the CD8 central memory pool. We performed additional analysis on residual PBMC using single cell network
profiling (SCNP).
Methods: The original trial randomized metastatic breast cancer patients to either 1 or 10 mg/kg of fresolimumab,
every 3 weeks for 5 cycles, combined with radiotherapy to a metastatic site at week 1 and 7 (22.5 Gy given in 3
doses of 7.5 Gy). Trial immune monitoring results were previously reported. In 15 patients with available residual
blood samples, additional functional studies were performed, and compared with data obtained in parallel from
seven healthy female donors (HD): SCNP was applied to analyze T cell receptor (TCR) modulated signaling via CD3
and CD28 crosslinking and measurement of evoked phosphorylation of AKT and ERK in CD4 and CD8 T cell subsets
defined by PD-1 expression.
Results: At baseline, a significantly higher level of expression (p < 0.05) of PD-L1 was identified in patient monocytes
compared to HD. TCR modulation revealed dysfunction of circulating T-cells in patient baseline samples as compared
to HD, and this was more pronounced in PD-1+ cells. Treatment with radiotherapy and fresolimumab did not resolve
this dyfunctional signaling. However, in vitro PD-1 blockade enhanced TCR signaling in patient PD-1+ T cells and not in
PD-1- T cells or in PD-1+ T cells from HD.
Conclusions: Functional T cell analysis suggests that baseline T cell functionality is hampered in metastatic breast cancer
patients, at least in part mediated by the PD-1 signaling pathway. These preliminary data support the rationale for
investigating the possible beneficial effects of adding PD-1 blockade to improve responses to TGFβ blockade and
radiotherapy.
Trial registration: NCT01401062.
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Introduction
Production of transforming growth factor-beta (TGFβ) is
increased in breast and other cancers, and elevated
TGFβ levels in blood correlate with worse patients out-
come [1, 2]. In addition to promoting metastasis and
therapy resistance [3, 4] TGFβ has broad immune sup-
pressive activity [5]. Inhibition of TGFβ improved anti-
tumor immune responses in pre-clinical studies [6, 7].
Radiation promotes the dissociation of TGFβ from
latency-associated peptide (LAP) [8], thus increasing its
active form in the tumor microenvironment. We have
previously shown in pre-clinical breast cancer models
that neutralization of TGFβ was required for the
radiotherapy-induced activation of tumor-specific CD8
T cells [9]. The anti-tumor T cells activated by radiother-
apy in the presence of TGFβ neutralization were able to
cause regression of the irradiated murine tumors and
non-irradiated metastases (abscopal effect), resulting in
significantly improved survival [9]. However, it was ob-
served that tumor regression in response to treatment
with radiotherapy and TGFβ blockade was often
followed by recurrence. The recurrence was significantly
delayed by addition of anti-PD-1 antibody, indicating
that an active PD-1/PD-L1 pathway limited the effective-
ness of the treatment [9].
Based on the beneficial effect on survival and tumor re-
gression observed in preclinical studies, we conducted a
phase I/II randomized clinical trial to test in advanced,
metastatic breast cancer patients the feasibility and efficacy
of combining TGFβ blockade by fresolimumab (GC1008), a
human IgG4 kappa monoclonal antibody that neutralizes
all mammalian isoforms of TGFβ [10], and radiotherapy.
Despite a lack of objective or abscopal responses, patients
treated with the higher dose of fresolimumab showed a lon-
ger median overall survival compared to those of patients
receiving the lower dose, suggesting that the treatment
could have elicited some degree of anti-tumor immune re-
sponse, capable of delaying tumor progression. An increase
in tumor-specific CD8 T cells during treatment was ob-
served in some patients, supporting this hypothesis [11].
However, in contrast with preclinical models, T cells elicited
in patients were clearly unable to cause tumor regression,
suggesting a role for other immunosuppressive pathways.
To gain more insights into the mechanisms underlying
the clinical findings, we performed functional studies of
the circulating T cells from the patients in this trial who
had sufficient residual blood specimens, using a multi-
parametric technique that enables the quantification of
functional immune signaling capacity at a single cell
level [12, 13]. When compared to healthy female donors
(HD), patients had evidence of T cell dysfunction at
baseline that was more pronounced in the PD-1+ subset.
Our investigation is limited by the small number of re-
sidual samples that could be analyzed. However, we were
able to obtain preliminary evidence about the relevance
of PD-1 pathway in advanced metastatic breast cancer.
Patients and methods
Study design and patients
The study design and procedures for the NCT01401062
trial were reported previously [11]. Briefly, patients with
stage IV breast cancer that had progressed after at least
one course of systemic therapy with at least three dis-
tinct metastatic sites were offered participation in a trial
testing fresolimumab and radiotherapy. Patients were
randomized to either of two doses of fresolimumab (1
versus 10 mg/kg) administered every 3 weeks (weeks 0,
3, 6, 9, 12). A metastatic site was chosen to receive con-
formal external beam radiation of 3 fractions of 7.5 Gy,
to a total of 22.5 Gy, on alternating days over the course
of week 1 and 7. The primary endpoint of the study was
abscopal response at week 15 based on Immunological
Response Criteria (irC) [14]. Results of this trial were re-
cently reported [11].
Single cell network profiling (SCNP) analysis of peripheral
blood lymphocytes
The SCNP assay was performed as described [13, 15]
using blood samples from healthy female donors (HD)
and patients. The mean age of patients analyzed for TCR
signaling was 55.3 (range 35–74) and for healthy donors
was 34.4 (range 20–59). We did not prioritize the ana-
lysis of a specific T cell subset, but in many cases we did
not have sufficient cells in the CD8 T cell compartment
to analyze the data and show significance. Briefly, per-
ipheral blood mononuclear cells (PBMC) were thawed
and aliquoted at 100,000 cells/well into 96-deep well
plates in RPMI 1640 + 10% FBS. After resting for 2 h at
37 °C cells were stained with antibodies directed against
PD-1 (clone EH12.1) and PD-L1 (clone MIH1, from BD
Biosciences) or were stimulated with anti-CD3-biotin
and anti-CD28-biotin (eBioscience) for 15 min, with
avidin crosslinking for the last 2 min, to investigate sig-
naling downstream of the T cell receptor (TCR). In some
assays cells were pre-treated with 1.5 μg/ml of either the
control isotype human IgG4 (Sigma) or pembrolizumab
(Merck) for 1 h at 37 °C prior to stimulation. Cells were
then fixed with 4% paraformaldehyde, permeabilized
with 100% methanol, and stained with a cocktail of
fluorochrome-conjugated antibodies recognizing cell
surface markers CD3, CD4 (BD Biosciences), CD8,
CD14 (Beckman Coulter), and antibodies recognizing
intracellular signaling molecules p-ERK (T202/T204), p-
AKT (S473). Live cells were gated using antibody against
cPARP (Asp214) (Nodality). Flow cytometry data were
acquired on a BD FACS Canto system using the FACS
DIVA software (BD Biosciences), and analyzed with
WinList (Verity House Software, Topsham, ME). Daily
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QC of the Canto cytometers was performed as previ-
ously described [15].
The response to TCR stimulation was measured using
p-AKT and p-ERK as a readout. The raw instrument
median fluorescence intensities (MFIs) were converted
to calibrated intensity metrics, Equivalent Number of
Reference Fluorophores (ERFs), by using rainbow cali-
bration particles. The “Fold” metric was applied to meas-
ure the level of a signaling molecule in a condition of
interest (e.g. modulated state) compared to its level in a
reference well (e.g. un-modulated state). A log2Fold
value of 1 implies a 2-fold change in ERF intensity
whereas a value close to 2 implies a 4-fold change. The
“Fold” metric is calculated as follows: log2Fold: log2
[ERF(modulated state)/ERF(un-modulated state)].
Statistical methods
Distribution of disease characteristics of patients with
and without adequate materials for SCNP evaluation
were summarized with descriptive statistics and com-
pared between the 1 mg/kg and 10mg/kg arms using
two sided Fisher’s Exact Tests. Baseline characteristics
were summarized with descriptive statistics by site and
compared between the 1 mg/kg and 10mg/kg arms for
patients with and without immuno modulatory receptors
and for patients with and without TCR signaling ana-
lysis. The quantitative variables were summarized using
means and SDs and medians with ranges for each arm
and compared using two-sided two sample T tests.
Qualitative variables were summarized by the distribu-
tions of the nominal levels and were compared using
two sided Fisher’s Exact Tests. No adjustments for mul-
tiple testing were used.
PBMC data obtained form SCNP were analyzed using
GraphPad Prism software (GraphPad version 6), and P
values were calculated using unpaired Student’s two-
tailed t-tests. All reported p values are two-sided and
statistical significance defined as p < 0.05.
Results
Results of the clinical study were previously reported
[11]. Briefly, there were no significant differences in the
distributions of the baseline patient characteristics, or
the number of infusions received between arm 1 and 2.
Patients in arm 2 had significantly lower risk of death
compared with arm 1 (HR arm 1 to arm 2: 2.73 with
95% CI: 1.02, 7.30; p = 0.039). However, there were no
objective abscopal responses, the primary endpoint of
the study, suggesting that blocking TGFβ with radiother-
apy was not sufficient to elicit an anti-tumor immune
response to control systemic tumor growth. We previ-
ously reported extensive phenotypic characterization of
circulating lymphocytes, revealing an increase in central
memory CD8 T cells and decreased myeloid-derived
suppressor cells (MDSCs) in the high dose fresolimumab
treatment group [11]. However, phenotypic analyses do
not provide information about cellular function. To
gather more insights into the barriers to clinical re-
sponse, PBMC were analyzed using SCNP [12, 13].
Residual blood samples were available from 15 out of
22 patients (6 of 11 from arm 1, and 9 of 11 from arm
2), although not all samples at each time point had suffi-
cient cells for each of the analyses performed. PBMC
from 7 HD were used for comparison. Based upon
demographic and clinical characteristics, the subset of
patients for whom sufficient samples were available is
representative of the patients in the entire treatment
group (Supplementary Table S1-S3).
For those patients with sufficient samples for SCNP
there was an elevated (p < 0.05) expression of PD-L1 in
patients’ monocytes compared to that in HD (Fig. 1a).
Expression of PD-1 on CD4 T cells was also elevated in
patient samples compared to HD (p = 0.07) (Fig. 1b). Pa-
tients randomized to arm 1 or 2 did not differ with re-
spect to the distributions of PD-L1 levels on monocytes
(arm 1 vs arm 2, mean 3.10 ± 1.7 vs 2.44 ± 1.13, p = 0.53)
or PD-1 levels on CD4 T cells (arm 1 vs arm 2, mean
0.51 ± 0.12 vs 0.59 ± 0.29, p = 0.53).
T cell functionality was evaluated by assessing signal-
ing downstream of the T cell receptor (TCR) in samples
obtained from subjects during the course of treatment.
At baseline, TCR modulated signaling as measured by p-
AKT levels was significantly (p < 0.005) lower in CD8 T
cells from patients compared to HD (Fig. 1c). On a cell
population-based analysis, including all samples col-
lected during treatment at weeks 5 and 15 for which
TCR modulated signaling could be evaluated, the evoked
p-AKT levels remained generally below the levels in HD
(Fig. 1c). For a few patients it was possible to compare
baseline and at least one post-treatment time point.
Some patients showed an increase, others no change or
a decrease from baseline in the evoked p-AKT levels. An
opposite trend was observed in the only two patients for
whom data were obtained for both week 5 and week 15
(Fig. 1d). Overall, this exploratory analysis suggests that
treatment with fresolimumab was insufficient to recover
T cell functionality in these patients.
Further analysis showed that TCR-modulated signaling
through p-AKT and p-ERK was consistently and signifi-
cantly lower in PD-1+ as compared to PD-1− T cells, in
both CD4 and CD8 T subsets from HD as well as base-
line samples from patients (Fig. 2a and b). This was most
evident in TCR modulated p-ERK signaling in CD8 cells
from patients and HD. To test whether PD-1 blockade
in vitro could restore TCR-modulated signaling, PBMC
were stimulated in the presence of anti-PD-1 antibody
pembrolizumab. PD-1 blockade was associated with in-
creased TCR-modulated signaling through p-AKT and
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p-ERK in PD-1+ CD4 T cells of patients. This effect was
not observed in PD-1− T cells (Fig. 3). Insufficient
cells were available to perform the same assessment
for CD8 T cells.
Overall, these results indicate that the patients en-
rolled in this study had impaired T cell functionality, and
suggest that TCR signaling was not corrected by treat-
ment with fresolimumab and radiotherapy. In vitro PD-1
blockade was able to increase TCR signaling in PD-1+
CD4 T cells in baseline samples, suggesting a role for
the PD-1 pathway in reduction of TCR signaling through
p-AKT and p-ERK in this patient population. Of note, 5
out of the 6 patients tested had hormone receptor-
positive (HR+) and 1 had HR +HER2+ breast cancer,
suggesting that T cell dysfunction is common in HR+
breast cancer. TCR signaling via p-AKT was reduced, al-
beit to a lesser degree, also in PD-1− CD4 and CD8 T
cells from patients compared to HD (Fig. 2a), and could
not be rescued by in vitro pembrolizumab, suggesting a
role for other immune checkpoints in the regulation of
TCR signaling in these T cell subsets.
Discussion
In an attempt to describe the immune resistance signa-
ture behind the lack of abscopal responses in a phase I/
II clinical trial of radiotherapy and fresolimumab in
metastatic breast cancer [11] we conducted SCNP ex-
ploratory studies. While phenotypic analyses provide in-
formation regarding the changes occurring in peripheral
blood during cancer treatment, they cannot establish the
relationship of these changes with cell subset functional-
ity. To measure the functional capacity of peripheral
blood T cells we applied SCNP analysis to patient and
HD PBMC, examining TCR modulated signaling via p-
AKT and p-ERK in T cell subsets defined by CD4/CD8
and PD-1 expression.
This analysis showed increased baseline levels of PD-1
on CD4 T cells, and PD-L1 on circulating monocytes of
breast cancer patient samples, as compared to HD. Im-
portantly, signaling downstream of the TCR was reduced
compared to HD in both CD8 and CD4 T cells at base-
line, and this was largely unaffected following treatment
with fresolimumab. Resolving this analysis to the level of
Fig. 1 Increased PD-L1 expression and decreased TCR signaling in breast cancer patients PBMC compared to HD. a-b Samples were analyzed at
baseline for expression of immunomodulatory receptors. a Significantly higher levels of PD-L1 on monocytes of breast cancer patients compared
to healthy donors (HD). b Higher levels of PD-1 on CD4 T cells of breast cancer patients compared to HD. c, d TCR modulated signaling in CD8 T
cells from HD and patients at baseline and during treatment, as measured by phosphorylation of AKT. c Analysis of all available samples from
patients treated in arm 1 (1 mg/kg of fresolimumab) and arm 2 (10 mg/kg of fresolimumab) shows overall reduced TCR signaling in CD8 T cells of
patients compared to HD. Each dot represents one individual. Unpaired t test, two-tailed, *p < 0.05, **P < 0.005. (D) pAKT values were plotted
overtime for 7 patients with baseline and at least one post-treatment sample measurements
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PD-1 expression and association, PD-1+ T cells consist-
ently showed lower TCR signaling as compared to PD-
1− T cells. Interestingly, in vitro PD-1 blockade with
pembrolizumab recovered, at least in part, the ability of
PD-1+ T cells from patients to signal through these path-
ways. These hypothesis-generating data provide prelim-
inary evidence that patients with advanced metastatic
breast cancer have dysfunctional TCR signaling through
p-AKT and p-ERK that is associated with PD-1 expres-
sion and that this is detectable in peripheral blood. It re-
mains to be tested if data obtained from PBMC may
serve to represent in part the interaction between PD-
L1+ monocytes and PD-1+ T cells that occur in the
tumor microenvironment: future studies are warranted
to examine such hypotheses using well annotated paired
PBMC and tumor samples from breast cancer patients.
While immunotherapy targeting PD-L1 in combin-
ation with chemotherapy has shown efficacy in meta-
static triple negative breast cancer [16], HR+ breast
cancer is poorly responsive to PD-1/PD-L1 blockade
[17]. Our data show that PD-1 blockade can improve
TCR signaling in T cells of HR+ breast cancer patients
(Fig. 3), suggesting that it should be tested as a compo-
nent of a combination therapy tailored to HR+ breast
cancer. A clinical trial designed to test the efficacy of
radiotherapy, endocrine therapy with or without CDX-
301 and anti-PD-1 (NCT03804944) will open soon.
Comparison of TCR modulated signaling in PD-1− T
cells from patients and HD revealed reduced signaling
through AKT but not ERK, in patient samples. These
data suggest the possibility that PD-1-independent in-
hibitory pathways are also up-regulated in the immune
cells of breast cancer patients. Due to the limited mater-
ial available for testing we were unable to further investi-
gate this possibility. The use of SCNP and similar assays
can be applied to assess ex vivo the functionality of T
cells and identify potential actionable targets.
An obvious limitation of our study is the small
number of patients with samples available for this
analysis. However, these data generated in primary pa-
tient samples are supported by additional preclinical
analyses. For example, we have previously shown in a
mouse model of breast cancer that dual blockade of
TGFβ and PD-1 with radiotherapy resulted in reduced
tumor recurrence and improved survival compared to
radiotherapy and blockade of either TGFβ or PD-1
alone [9]. Additionally, in other tumor types, dual
blockade of TGFβ and PD-1 in a mouse model of T
Fig. 2 PD-1+ CD4 and CD8 T cells show decreased TCR signaling compared to PD-1- T cells. a, b The response to TCR stimulation was measured
using p-AKT and p-ERK as a readout. PD1+ T cells from both HD and patients collected at baseline show significantly reduced TCR modulated
signaling compared to PD1− T cells, as measured by phosphorylation of AKT (a) and ERK (b). Significantly reduced TCR modulated AKT
phosphorylation is also evident in PD1− T cells from patients compared to HD. Each dot represents one individual and data is represented as
Log2Fold value. A log2Fold value of 1 implies a 2-fold change in Equivalent Number of Reference Fluorophores (ERFs) intensity whereas a value
close to 2 implies a 4-fold change. *p < 0.05, **P < 0.005, ***P < 0005
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cell exclusion induced immune-mediated tumor re-
gression [18] and in a mouse model of colorectal can-
cer, blockade of TGFβ signaling rendered tumors
susceptible to antibodies targeting PD-1/PD-L1 [19].
Together these data serve as the basis for hypothesis
testing in future studies.
Recent evidence has highlighted a key role of stro-
mal TGFβ signaling in preventing tumor infiltration
by activated T cells [20]. In urothelial cancer patients
TGFβ signaling was associated with T cell exclusion
and resistance to anti-PD-L1 antibody treatment [18].
In totality, these data, when combined with the clin-
ical findings of the trial [11] encourage additional
clinical testing of combined radiotherapy with both
TGFβ and PD-1 blockade in breast cancer. A new bi-
functional fusion protein targeting PD-L1 and TGFβ,
Fig. 3 Anti-PD-1 antibody restores TCR signaling in PD-1+ CD4 T cells from breast cancer patients. a-d PBMC from HD (Left panels) and patients
(Right panels) were stimulated with anti-CD3 and anti-CD28 in the presence of anti-PD-1 antibody pembrolizumab (anti-PD-1) or isotype control
antibody (Isotype). Graphs show the results for PD1+ T cells, as measured by phosphorylation of AKT (a) and ERK (b). Stimulation in the presence
of anti-PD-1 did not significantly increase the response of PD1+ CD4 T cells from HD, but increased the response of PD-1+ CD4 T cells from
patients, achieving significance as measured by AKT phosphorylation and showing a trend to significance, as measured by ERK phosphorylation.
Stimulation in the presence of anti-PD-1 did not significantly increase the response of PD1− CD4 T cells from HD and patients as measured by
phosphorylation of AKT (c) or ERK (d). Each line corresponds to one individual. T test, two-tailed, *p < 0.05, **P < 0.005
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which is undergoing early clinical testing [21], is a
promising candidate for this approach. The emerging
data in multiple cancers support a role of TGFβ and
PD-1 blockade as critical components of a multi-
pronged approach to overcome immune resistance of
breast cancer.
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